Physician profile
David Itkin
NPI 1760476667
$585.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $69.96 · 2021: $110 · 2022: $92.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $120.55 | 2019-2021 | |
| Abbvie INC. | $92.39 | 2022 | |
| Astellas Pharma US INC | $71.68 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.69 | 2019 | |
| Viiv Healthcare Company | $54.23 | 2019-2020 | |
| Insmed, INC. | $40.46 | 2019 | |
| Janssen Biotech, INC. | $34.99 | 2019 | |
| Janssen Products, Lp | $31.49 | 2021 | |
| Glaxosmithkline, LLC. | $21.20 | 2019 | |
| Melinta Therapeutics, LLC | $19.65 | 2019 | |
| Sanofi Pasteur INC. | $14.60 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $14.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Itkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.